sj-docx-1-tan-10.1177_17562864211042458 – Supplemental material for No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Butzkueven, Helmut; Kappos, Ludwig; Spelman, Tim; Trojano, Maria; Wiendl, Heinz; Su, Ray; Liao, Shirley; Hyde, Robert; Licata, Stephanie; Ho, Pei-Ran; Campbell, Nolan

doi:10.25384/SAGE.16695689.v1

sj-docx-1-tan-10.1177_17562864211042458.docx (55.03 kB)

sj-docx-1-tan-10.1177_17562864211042458 – Supplemental material for No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

journal contribution

posted on 2021-09-29, 00:06 authored by Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho, Nolan Campbell

Supplemental material, sj-docx-1-tan-10.1177_17562864211042458 for No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP) by Helmut Butzkueven, Ludwig Kappos, Tim Spelman, Maria Trojano, Heinz Wiendl, Ray Su, Shirley Liao, Robert Hyde, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Therapeutic Advances in Neurological Disorders